On September 27, 2026, Hutchmed (NASDAQ: HCM) announced the initiation of the Phase Ia segment of a global clinical trial investigating HMPL-A830, a novel thera...
Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.